Pharmaceutical Strategy Could Save European ATMP Development
Better RWE Infrastructure And Pricing Models Also Key To European ATMP Sector
The European Commission’s Pharmaceutical Strategy should end regulatory “carve outs” like the hospital exemptions, and innovate pricing and reimbursement structures, says the Alliance for Regenerative Medicines.
You may also be interested in...
The need to accelerate clinical trials of products for treating and preventing coronavirus has led the EU authorities to propose a more streamlined process for allowing the release of GMO-containing investigational medicinal products into the environment.
Pharmaceutical industry groups say the European Commission’s Pharmaceutical Strategy Roadmap lacks detail on delivering a faster regulatory process and encouraging competitiveness.
Industry access to real world data for regulatory and market access purposes in Asia Pacific compares poorly with the US.